Taïeb D, Sebag F, Hubbard J G, Mundler O, Henry J F, Conte-Devolx B
Service central de Biophysique et de Médecine Nucléaire, Centre hospitalo-universitaire de la Timone, Marseille, France.
Clin Endocrinol (Oxf). 2004 Jul;61(1):102-8. doi: 10.1111/j.1365-2265.2004.02077.x.
To assess the impact of [(131)I]meta-iodobenzylguanidine ((131)MIBG) scintigraphy on the management of phaeochromocytoma.
Between 1982 and 2002, 83 patients with histologically proven phaeochromocytoma or paraganglioma were investigated using (131)MIBG scintigraphy. Seventeen of these patients, with a hereditary form of the disease, presented with 23 phaeochromocytomas [three neurofibromatosis type 1 (NF1), five von Hippel-Lindau disease (VHL), eight multiple endocrine neoplasia type 2A (MEN2A) and one type 2B (MEN2B)].
MIBG uptake was observed in 44/54 sporadic phaeochromocytomas (sensitivity 81.5%), 14/23 familial phaeochromocytomas (60.9%), 3/6 paragangliomas and 4/6 malignant phaeochromocytomas. No significant correlations were found between the degree of tracer uptake, tumour size and urinary metanephrine levels. No patients undergoing surgery for sporadic phaeochromocytoma had a second tumour located. Nine of 54 sporadic phaeochromocytomas had normal or mildly elevated urinary metanephrine levels (< 1.5 greater than normal). In eight of these patients, (131)MIBG was positive and confirmed the diagnosis of phaeochromocytoma. In malignant phaeochromocytomas (n = 6), MIBG demonstrated additional lesions not detected with computed tomography (CT) and/or magnetic resonance imaging (MRI) in three cases. The MIBG findings in the group with apparently sporadic paragangliomas (n = 6) were negative in four cases and failed to detect a cervical lesion in one multifocal paraganglioma.
(131)MIBG was useful in confirming the diagnosis in phaeochromocytomas with low levels of catecholamine secretion. It contributed little to the management of patients when used as a means of screening for multifocality in sporadic phaeochromocytoma, or the management of patients with familial phaeochromocytoma. However, MIBG can be an informative method of investigation when dealing with malignant/ectopic forms, although the sensitivity of MIBG is lower in this group of patients.
评估[¹³¹I]间碘苄胍(¹³¹MIBG)闪烁扫描术对嗜铬细胞瘤治疗的影响。
1982年至2002年间,对83例经组织学证实为嗜铬细胞瘤或副神经节瘤的患者进行了¹³¹MIBG闪烁扫描术检查。其中17例患有遗传性疾病的患者共出现23个嗜铬细胞瘤[3例1型神经纤维瘤病(NF1)、5例冯·希佩尔-林道病(VHL)、8例2A型多发性内分泌腺瘤病(MEN2A)和1例2B型(MEN2B)]。
在54个散发性嗜铬细胞瘤中有44个观察到MIBG摄取(敏感性81.5%),23个家族性嗜铬细胞瘤中有14个(60.9%),6个副神经节瘤中有3个,6个恶性嗜铬细胞瘤中有4个。示踪剂摄取程度、肿瘤大小与尿间甲肾上腺素水平之间未发现显著相关性。接受散发性嗜铬细胞瘤手术的患者中没有发现第二个肿瘤。54个散发性嗜铬细胞瘤中有9个尿间甲肾上腺素水平正常或轻度升高(<正常上限1.5倍)。其中8例患者¹³¹MIBG呈阳性,确诊为嗜铬细胞瘤。在恶性嗜铬细胞瘤(n = 6)中,MIBG在3例中显示出计算机断层扫描(CT)和/或磁共振成像(MRI)未检测到的额外病灶。在明显为散发性副神经节瘤组(n = 6)中,MIBG检查结果4例为阴性,1例多灶性副神经节瘤未检测到颈部病灶。
¹³¹MIBG有助于确诊儿茶酚胺分泌水平低的嗜铬细胞瘤。在用于筛查散发性嗜铬细胞瘤的多灶性或家族性嗜铬细胞瘤患者的治疗时,它对患者治疗的贡献不大。然而,在处理恶性/异位型嗜铬细胞瘤时,MIBG可能是一种有价值的检查方法,尽管该组患者中MIBG的敏感性较低。